Advertisement

Related Videos

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Opening Session Panel Discussion

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Opportunities to Optimize Cancer Policies Panel Discussion

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Advertisement

Advertisement




Feb
23
Today In Oncology
Multiple Myeloma FDA Approves Daratumumab and Hyaluronidase-fihj in Combination With VRd
FDA Releases Draft Guidance for Use of MRD and CR as Primary Endpoints in Multiple Myeloma Trials
ASH 2025: Highlights in Relapsed/Refractory Multiple Myeloma
New Biomarker May Predict Chemotherapy Response in Patients With Triple-Negative Breast Cancer
Acral Melanoma Ancestry and Genetics Impact Outcomes
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo